Dasatinib

The dosage of Dasatinib is highly individualized based on the type of leukemia being treated and the patient's response to the medication. According to clinical guidelines:

• Chronic Phase CML: The standard starting dose for adults is 100 mg taken once daily. This dose may be increased to 140 mg if the disease does not respond adequately, or decreased to 80 mg, 50 mg, or 20 mg to manage side effects.
• Accelerated Phase CML, Blast Phase CML, or Ph+ ALL: The standard starting dose is 140 mg taken once daily. This higher dose is necessary because these phases of leukemia are more aggressive and often require more intensive kinase inhibition.

For pediatric patients (children 1 year and older), the dose is calculated based on body weight. The following is a general guideline for chronic phase CML or Ph+ ALL (in combination with chemotherapy):

• Weight 10 kg to <20 kg: 40 mg once daily.
• Weight 20 kg to <30 kg: 60 mg once daily.
• Weight 30 kg to <45 kg: 70 mg once daily.
• Weight 45 kg or more: 100 mg once daily.

Dosage may be adjusted by the pediatric oncologist based on the child's blood counts and tolerance. Dasatinib is not recommended for infants under one year of age.

Renal Impairment

Since less than 4% of Dasatinib is excreted by the kidneys, no specific dose adjustments are typically required for patients with mild to moderate renal impairment. However, clinicians exercise caution in patients with severe kidney disease as clinical data in this population is limited.

Hepatic Impairment

Because Dasatinib is primarily metabolized by the liver, patients with hepatic impairment (liver dysfunction) may experience higher levels of the drug in their bloodstream. While the FDA does not mandate a specific starting dose reduction for mild hepatic impairment, those with moderate to severe impairment (Child-Pugh Class B or C) should be monitored very closely, and a dose reduction may be considered by the treating physician.

Elderly Patients

No specific dose adjustment is required based solely on age. However, elderly patients (65 and older) are more likely to experience side effects such as fluid retention and shortness of breath. Close monitoring for these complications is essential in the geriatric population.

To ensure the medication works effectively, patients should follow these administration guidelines:

• Consistency: Take Dasatinib at the same time every day to maintain steady levels in the blood.
• Food: Dasatinib can be taken with or without food. However, it should NOT be taken with grapefruit or grapefruit juice, as these can increase drug levels to dangerous points.
• Swallow Whole: Tablets must be swallowed whole. Do not crush, chew, or break them. Crushing the tablets can lead to an immediate release of the drug, increasing toxicity, and poses a risk to anyone handling the broken tablets.
• Stomach Acid: Avoid taking antacids (like Tums or Mylanta) within 2 hours before or 2 hours after taking Dasatinib. If you take H2 blockers (like famotidine) or PPIs (like omeprazole), discuss this with your doctor, as they may need to change your regimen to ensure Dasatinib is absorbed.
• Storage: Store at room temperature (20°C to 25°C) in a dry place away from children.

If you miss a dose of Dasatinib, skip the missed dose and take your next scheduled dose at the regular time. Do not take two doses at once to make up for a missed one. If you frequently forget doses, consider using a pill organizer or alarm, as consistent dosing is vital for controlling leukemia.

Signs of a Dasatinib overdose may include severe low blood counts (leading to bleeding or infection) and severe fluid retention. If an overdose is suspected, contact a Poison Control Center or seek emergency medical attention immediately. There is no specific antidote for Dasatinib; treatment is supportive and focuses on managing symptoms.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this could allow the leukemia to progress.

Dasatinib is a potent medication that affects many systems in the body. The most frequently reported side effects include:

• Myelosuppression: This is a decrease in bone marrow activity, resulting in fewer red blood cells (anemia), white blood cells (neutropenia), and platelets (thrombocytopenia). Patients may feel unusually tired, develop frequent infections, or notice easy bruising.
• Fluid Retention: This is a hallmark side effect of Dasatinib. It can manifest as peripheral edema (swelling of the hands, ankles, or feet) or more seriously as pleural effusion (fluid around the lungs). You may notice sudden weight gain or a 'puffy' appearance.
• Gastrointestinal Issues: Diarrhea is very common, occurring in about 30% of patients. Nausea, vomiting, and abdominal pain are also frequently reported, though these often subside as the body adjusts to the medication.
• Fatigue and Headache: Many patients report a general sense of tiredness and persistent headaches, especially during the first few weeks of therapy.
• Skin Rash: A mild to moderate red, itchy rash may appear on the trunk or limbs.
• Musculoskeletal Pain: Aching in the joints, muscles, or bones is a common complaint.

• Congestive Heart Failure: Some patients may develop weakened heart muscle, leading to shortness of breath and exercise intolerance.
• QT Prolongation: This is an alteration in the heart's electrical rhythm, which can be detected on an EKG. While often asymptomatic, it can lead to palpitations.
• Visual Disturbances: Blurred vision or dry eyes may occur.
• Insomnia: Difficulty falling or staying asleep.
• Febrile Neutropenia: A fever occurring while white blood cell counts are dangerously low, requiring immediate hospitalization.

• Pulmonary Arterial Hypertension (PAH): High blood pressure in the arteries of the lungs. This is a rare but life-threatening condition that can occur at any time during treatment.
• Tumor Lysis Syndrome: A condition where cancer cells die so rapidly they release their contents into the blood, potentially causing kidney failure.
• Severe Dermatologic Reactions: Rare cases of Stevens-Johnson Syndrome have been reported.

> Warning: Stop taking Dasatinib and call your doctor immediately if you experience any of these serious symptoms:

• Shortness of Breath: Especially if it occurs while resting or lying down, as this may indicate fluid in the lungs (pleural effusion) or heart failure.
• Chest Pain or Palpitations: May indicate heart rhythm issues or a heart attack.
• Unusual Bleeding: Bloody stools, coughing up blood, or heavy menstrual bleeding, which could indicate severe thrombocytopenia or internal hemorrhage.
• Fever and Chills: Any temperature over 100.4°F (38°C) should be reported immediately as it may signify a dangerous infection.
• Sudden Weight Gain: Gaining more than 3-5 pounds in a single week may indicate severe fluid retention.
• Yellowing of the Skin/Eyes: Signs of liver toxicity (jaundice).

Prolonged use of Dasatinib can lead to chronic issues. The most significant concern is the cumulative risk of pleural effusions, which may require repeated medical procedures to drain the fluid. There is also a risk of cardiovascular events, including atherosclerosis (hardening of the arteries), which requires long-term monitoring of cholesterol and blood pressure. Additionally, long-term TKIs may affect bone metabolism, though this is still being studied in adult populations.

As of 2024, Dasatinib (Sprycel) does not carry an FDA Black Box Warning. However, it does carry several 'Warnings and Precautions' that are considered nearly as critical, particularly regarding myelosuppression and fluid retention. Healthcare providers treat these with the highest level of vigilance, often performing weekly blood counts during the first two months of therapy.

Report any unusual symptoms to your healthcare provider immediately. Early intervention for side effects often allows patients to remain on the medication at a lower dose rather than discontinuing it entirely.

Dasatinib is a high-risk medication that requires careful management by an oncology specialist. Patients must be aware that while this drug is effective against leukemia, it can suppress the immune system and affect organ function. It is vital to maintain all follow-up appointments and laboratory tests. You should inform all of your healthcare providers, including dentists and pharmacists, that you are taking a tyrosine kinase inhibitor.

Currently, there are no FDA black box warnings for Dasatinib. However, the FDA-approved labeling includes significant warnings regarding life-threatening pleural effusions and severe myelosuppression that require immediate clinical action if they occur.

• Myelosuppression: Dasatinib frequently causes severe neutropenia (low white cells), thrombocytopenia (low platelets), and anemia. This increases your risk of life-threatening infections and spontaneous bleeding. Complete blood counts (CBCs) must be performed weekly or bi-weekly initially.
• Fluid Retention: Dasatinib is associated with severe fluid retention in up to 10% of patients. This includes pleural effusion (fluid in the lung lining), pericardial effusion (fluid around the heart), and ascites (fluid in the abdomen). Patients with pre-existing heart disease are at higher risk.
• Cardiovascular Toxicity: There is a risk of heart failure, left ventricular dysfunction, and myocardial infarction. Patients should be screened for cardiovascular risk factors before starting therapy.
• Pulmonary Arterial Hypertension (PAH): Dasatinib can cause high blood pressure in the lung arteries. This may be reversible if the drug is stopped, but it can be fatal if not caught early. Symptoms include permanent shortness of breath and fatigue.
• QT Prolongation: Dasatinib may prolong the QT interval on an EKG, which can lead to a dangerous heart rhythm called Torsade de Pointes. This risk is higher if you have low potassium or magnesium levels.
• Hemorrhage: Both severe internal bleeding (including gastrointestinal and CNS bleeds) and superficial bleeding have been reported. This is often, but not always, related to low platelet counts.

To ensure safety, your doctor will require the following tests:

• Complete Blood Count (CBC): Weekly for the first 2 months, then monthly or as clinically indicated.
• Liver Function Tests (LFTs): To monitor for hepatotoxicity.
• Renal Function Tests: To monitor kidney health.
• Electrolytes: Specifically potassium and magnesium, to prevent heart rhythm issues.
• EKGs: To monitor the QT interval, especially in patients with heart disease.
• Chest X-rays: If you develop a cough or shortness of breath, to check for fluid around the lungs.

Dasatinib may cause dizziness or blurred vision in some patients. Do not drive or operate heavy machinery until you know how the medication affects you. If you experience significant fatigue or 'brain fog,' use caution when performing tasks that require alertness.

There is no direct contraindication between Dasatinib and moderate alcohol consumption. However, alcohol can strain the liver, which is already processing the Dasatinib. Furthermore, alcohol can worsen the dehydration associated with diarrhea. It is best to limit alcohol intake and discuss your habits with your oncologist.

Do not stop taking Dasatinib suddenly. Stopping a TKI can lead to a 'rebound' effect where the leukemia cells begin to multiply rapidly again. If the drug must be stopped due to toxicity, your doctor will provide a specific plan. There is no traditional 'withdrawal syndrome,' but the risk of cancer progression is the primary concern upon discontinuation.

> Important: Discuss all your medical conditions, especially heart, liver, or lung disease, with your healthcare provider before starting Dasatinib.

Certain drugs should never be used with Dasatinib because they can cause life-threatening toxicity or make the Dasatinib completely ineffective:

• Strong CYP3A4 Inducers: Medications like Rifampin, Phenytoin, Carbamazepine, and Phenobarbital significantly speed up the metabolism of Dasatinib. This can reduce Dasatinib levels by over 80%, rendering the cancer treatment ineffective.
• Proton Pump Inhibitors (PPIs): Drugs like Omeprazole, Esomeprazole, and Lansoprazole suppress stomach acid for long periods. Dasatinib requires acid to dissolve. PPIs can reduce Dasatinib absorption by nearly 50%. These should be avoided; H2 blockers or antacids are preferred if timed correctly.

• Strong CYP3A4 Inhibitors: Drugs like Ketoconazole, Itraconazole, Clarithromycin, and Ritonavir slow down the breakdown of Dasatinib. This can increase the concentration of Dasatinib in the blood five-fold, leading to severe bone marrow suppression and heart issues.
• QT-Prolonging Drugs: Using Dasatinib with other drugs that affect heart rhythm (like Amiodarone, Sotalol, or Ziprasidone) increases the risk of fatal arrhythmias.
• Anticoagulants and Antiplatelets: Taking Warfarin, Clopidogrel, or high-dose Aspirin with Dasatinib significantly increases the risk of severe bleeding, as Dasatinib already lowers platelet counts and may inhibit platelet function.

• H2 Blockers: Medications like Famotidine (Pepcid) can be used, but they must be taken at least 10 hours before or 2 hours after the Dasatinib dose to minimize the impact on absorption.
• Moderate CYP3A4 Inhibitors/Inducers: Drugs like Verapamil or Erythromycin may require a Dasatinib dose reduction.

• Grapefruit and Grapefruit Juice: These contain compounds that inhibit the CYP3A4 enzyme in the gut. Consuming grapefruit can lead to unpredictably high levels of Dasatinib in the blood. Avoid all grapefruit products.
• St. John's Wort: This herbal supplement is a potent inducer of CYP3A4 and will significantly lower the effectiveness of your leukemia treatment.
• High-Fat Meals: While Dasatinib can be taken with food, extremely high-fat meals may slightly increase absorption. It is best to be consistent with your meal types when taking the medication.

• Vitamin E: High doses may increase bleeding risk.
• Garlic Supplements: May have mild anti-platelet effects and interact with CYP enzymes.
• Antacid Supplements: Calcium carbonate or magnesium hydroxide supplements should be spaced at least 2 hours apart from Dasatinib.

Dasatinib does not typically interfere with the chemical assays of most lab tests, but it will profoundly change the results of blood tests (e.g., lowering white blood cell counts). It may also cause false elevations in serum creatinine in rare instances due to competition for renal transport, though this is not a common clinical concern.

For each major interaction, the mechanism usually involves the Cytochrome P450 3A4 enzyme system. Inhibition of this enzyme leads to toxic accumulation, while induction leads to therapeutic failure. Management strategies usually involve selecting alternative non-interacting medications or preemptively adjusting the Dasatinib dose by 20-50% under strict oncology supervision.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even over-the-counter vitamins can change how Dasatinib works.

There are very few absolute contraindications for Dasatinib, given its role in treating life-threatening cancer. However, the following apply:

• Hypersensitivity: Dasatinib must NEVER be used in patients with a known severe allergy or anaphylactic reaction to Dasatinib or any of the inactive ingredients in the tablet (such as lactose monohydrate, microcrystalline cellulose, or croscarmellose sodium). An allergic reaction can cause swelling of the face, difficulty breathing, and a dangerous drop in blood pressure.
• Pregnancy: Dasatinib is contraindicated in pregnancy due to its mechanism of action as a kinase inhibitor, which is essential for fetal development. It is known to cause fetal harm and limb abnormalities. Use is only considered if the benefit to the mother significantly outweighs the certain risk to the fetus, which is rare.

These are conditions where the drug should be used with extreme caution and only after a thorough risk-benefit analysis:

• Pre-existing Pleural Effusion: Since Dasatinib causes fluid around the lungs, patients who already have this condition are at very high risk for respiratory failure.
• Long QT Syndrome: Patients with congenital long QT syndrome or those with uncorrected hypokalemia (low potassium) should avoid Dasatinib if possible, as it can trigger fatal heart rhythms.
• Severe Hepatic Impairment: Patients with Child-Pugh Class C liver disease have significantly altered drug clearance. The risk of toxicity is very high, and alternative therapies may be preferred.
• Active Bleeding: Patients with an active peptic ulcer or recent intracranial hemorrhage should not start Dasatinib until the bleeding is controlled and platelet counts are stable.

While Dasatinib is chemically distinct from other TKIs like Imatinib (Gleevec) or Nilotinib (Tasigna), some patients who experience severe skin rashes or liver toxicity with one TKI may experience a similar reaction with another. However, many patients who are 'intolerant' to Imatinib (meaning they had bad side effects) can tolerate Dasatinib quite well. There is no known cross-reactivity with common antibiotics or non-cancer medications.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to cancer therapies, before prescribing Dasatinib.

Dasatinib is classified as a drug that can cause fetal harm (formerly FDA Category D). Based on its mechanism of action and findings in animal studies, Dasatinib can cause embryo-fetal toxicity when administered to a pregnant woman. There are reports of hydrops fetalis (severe swelling in the newborn) and fetal skeletal malformations in humans.

• Contraception: Females of reproductive potential should use effective contraception during treatment and for at least 30 days after the final dose.
• Males: It is currently unknown if Dasatinib is present in semen, but as a precaution, men with pregnant partners should discuss safety with their doctor.

It is not known whether Dasatinib or its metabolites are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants—including severe blood count suppression—breastfeeding is not recommended during treatment with Dasatinib and for at least 2 weeks after the last dose.

Dasatinib is FDA-approved for use in children 1 year of age and older for Ph+ CML in the chronic phase and Ph+ ALL (in combination with chemotherapy).

• Growth Monitoring: There have been reports of bone growth changes and delayed puberty in children taking TKIs. Pediatricians must monitor height and weight closely.
• Dosing: Dosing is strictly weight-based. The safety and effectiveness in children under 1 year of age have not been established.

In clinical trials, approximately 10-15% of patients were 65 years of age or older. While the effectiveness of the drug is similar across age groups, elderly patients are more likely to experience side effects, particularly:

• Pleural effusion (fluid in the lungs)
• Dyspnea (shortness of breath)
• Fatigue
• Congestive heart failure

Physicians often start elderly patients on the standard dose but have a lower threshold for reducing the dose if side effects appear.

Specific studies in patients with decreased renal function have not been conducted. However, since renal excretion is a minor route of elimination, no dose adjustment is generally recommended for patients with kidney disease. Patients on dialysis do not require supplemental doses as the drug is highly protein-bound and not likely to be cleared by the dialysis machine.

Dasatinib is primarily metabolized by the liver. Patients with moderate to severe hepatic impairment should be treated with caution. The exposure to the drug can be increased in these patients, raising the risk of toxicity. Your doctor may perform more frequent liver function tests and may consider a lower starting dose if you have significant liver scarring (cirrhosis).

> Important: Special populations require individualized medical assessment. Always disclose your full health status to your oncology team.

Dasatinib is a small-molecule inhibitor of multiple tyrosine kinases. Its primary target is the BCR-ABL fusion protein, which is the causative agent in Philadelphia chromosome-positive leukemias. It binds to the ATP-binding site of the BCR-ABL enzyme with a much higher affinity than Imatinib (approximately 325 times more potent in vitro).

Beyond BCR-ABL, Dasatinib inhibits the SRC family kinases (SRC, LCK, YES, FYN). SRC kinases are involved in the pathways that allow cancer cells to migrate, survive, and resist other treatments. By inhibiting SRC, Dasatinib can often overcome Imatinib resistance caused by BCR-ABL mutations (except for the T315I mutation). It also targets c-KIT, EPHA2, and PDGFRβ, which are involved in various cell signaling and growth pathways.

The relationship between Dasatinib plasma concentration and BCR-ABL inhibition is well-established. Higher concentrations lead to greater suppression of leukemic clones. The duration of kinase inhibition with once-daily dosing is sufficient to maintain clinical response, even though the drug has a short half-life. Tolerance to the therapeutic effect (where the drug stops working) is usually due to new genetic mutations in the leukemia cells rather than a change in how the body processes the drug.

| Parameter | Value |

|---|---|

| Bioavailability | Variable (pH dependent) |

| Protein Binding | ~96% (to Albumin) |

| Half-life | 3 to 5 hours |

| Tmax | 0.5 to 3 hours |

| Metabolism | Hepatic (Primary CYP3A4) |

| Excretion | Fecal 85%, Renal 4% |

• Molecular Formula: C22H26ClN7O2S
• Molecular Weight: 488.01 g/mol
• Solubility: Very slightly soluble in water; solubility is highly dependent on pH (insoluble at pH > 4.0).
• Structure: Dasatinib is a substituted aminothiazole. It appears as a white to off-white powder in its raw form.

Dasatinib is classified as a Second-Generation Tyrosine Kinase Inhibitor (TKI). It is part of the broader category of targeted therapies or 'precision medicine' in oncology. Related medications in this class include Nilotinib (Tasigna), Bosutinib (Bosulif), and Ponatinib (Iclusig).